Premium
Stem cell factor receptor (c‐kit, CD117) is expressed on blast cells from most immature types of acute myeloid malignancies but is also a characteristic of a subset of acute promyelocytic leukaemia
Author(s) -
Di Noto R.,
Lo Pardo C.,
Schiavone E. M.,
Manzo C.,
Vacca C.,
Ferrara F.,
Del Vecchio L.
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.395932.x
Subject(s) - cd117 , precursor cell , acute promyelocytic leukemia , cd34 , stem cell , myeloid , cancer research , receptor , immunology , retinoic acid , biology , medicine , in vitro , cell culture , microbiology and biotechnology , biochemistry , genetics
Investigating 208 patients with acute haematological malignancies, we found that stem cell factor receptor (SCFR) was expressed on high numbers of blast cells from the vast majority of patients (93%) with refractory anaemia with excess of blasts in transformation. SCFR was also detected in 62% of AMLs, in which it was directly associated to the expression of CD7, interleukin 6 receptor and CD34, and inversely to that of CD11b and CD14. SCFR‐positive cases were preferentially represented in AML‐M1 (70%) and in AML‐M2 (83%) subsets, whereas only 45% of the remaining samples (M3–M4–M5) exhibited SCFR positivity. Interestingly, 50% of cases with acute promyelocytic leukaemia expressed SCFR and this molecule was heterogenously regulated by in vitro treatment with all‐ trans retinoic acid.